RxDoctor Payments Data

Karthik Ravindran, MD

Internal Medicine · Saginaw, MINPI 1770993594

Payments from drug & device makers

$350in general payments, 2019–2025

Across 18 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$60
  • GSK$42
  • Cipher Pharmaceuticals US LLC$41
  • Mylan Specialty L.p.$37
  • Novo Nordisk$35
  • Pfizer$30
  • plus $106 from 6 others

What the payments were for

  • Food & beverage$350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Xeris Pharmaceuticals, Inc.3$60
GSK2$42
Cipher Pharmaceuticals US LLC1$41
Mylan Specialty L.p.2$37
Novo Nordisk2$35
Pfizer2$30
Boston Scientific1$24
AbbVie1$21
Novartis1$18
Amgen1$17
Kowa Pharmaceuticals America, Inc.1$14
Organon1$12

How this compares

$350 in reported general payments places this provider in the 55th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$1,096
Medicare patients
43
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide182$249,381
JardianceEmpagliflozin184$217,009
EliquisApixaban73$76,516
OzempicSemaglutide50$70,468
FarxigaDapagliflozin Propanediol61$69,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$58,699
EntrestoSacubitril/Valsartan28$26,880
XareltoRivaroxaban15$20,170
JanuviaSitagliptin Phosphate20$20,110
Incruse ElliptaUmeclidinium Bromide44$18,540
LinzessLinaclotide29$15,810
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$15,319
RybelsusSemaglutide12$14,570
Lantus SolostarInsulin Glargine,hum.Rec.Anlog99$14,030
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$85,03862 claims
PfizerEliquis, Abrysvo$30$84,19895 claims
GSKTrelegy Ellipta, Incruse Ellipta, Shingrix$42$83,349135 claims
NovartisEntresto$18$26,88028 claims
AbbVieLinzess$21$15,81029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →